$155.47
+1.65%
N/A+$2.52
의료
생명공학
NASDAQ
활발히 거래 중
Palvella Therapeutics, Inc.는 중증이고 흔치 않은 유전성 피부 질환으로 고통받는 환자들을 위한 혁신적 치료제의 발견, 개발, 상용화를 목적으로 하는 임상 단계 바이오제약 ...
Palvella Therapeutics, Inc.는 중증이고 흔치 않은 유전성 피부 질환으로 고통받는 환자들을 위한 혁신적 치료제의 발견, 개발, 상용화를 목적으로 하는 임상 단계 바이오제약 ...
Palvella Therapeutics, Inc. is a clinical-stage biotechnology company listed on the Nasdaq Global Market under the symbol PVLA. The company is headquartered at 353 West Lancaster Avenue in Wayne, Pennsylvania, and reported approximately 29 full-time employees. Founded in 2015, Palvella concentrates on rare genetic, dermatological, and vascular diseases for which treatment options may be limited and where the underlying biology can involve the mechanistic target of rapamycin, or mTOR, pathway. Palvella's central technology is the QTORIN platform, a proprietary drug-delivery approach designed to deliver active pharmaceutical ingredients locally to affected tissues. Its principal development program is QTORIN 3.9% rapamycin anhydrous gel, commonly referred to as QTORIN rapamycin. The product is being studied in Phase 3 clinical trials for microcystic lymphatic malformations, rare abnormalities of the lymphatic vessels, and in Phase 2 trials for cutaneous venous malformations. The company is also evaluating QTORIN rapamycin for additional dermatological diseases associated with mTOR-pathway activity. The platform's intended value proposition is localized treatment for conditions that can be difficult to manage with existing systemic or procedural approaches, although clinical efficacy, safety, regulatory approval, reimbursement, and commercial adoption remain important uncertainties. Wesley H. Kaupinen, also known as Wes Kaupinen, is the founder and chief executive officer. Publicly identified leadership also includes Matthew E. Korenberg as chief financial officer, Jeff Martini, Ph.D., as chief scientific officer, and Ashley Kline in the leadership organization. Management has indicated that preparations for a potential U.S. launch of QTORIN rapamycin for microcystic lymphatic malformations include building market-access and patient-services capabilities. Palvella is not yet a commercial-revenue-generating pharmaceutical company according to the supplied trailing-twelve-month data. Reported revenue and gross profit margins are zero, while the company remains loss-making and generates negative operating and free cash flow. The supplied figures show approximately $2.26 billion in market capitalization, enterprise value of about $2.08 billion, cash per share of approximately $17.46, and a current ratio of about 21.18. These metrics suggest substantial liquidity relative to current liabilities, but they do not eliminate the need for future financing if development and commercialization expenses continue. No detailed bill of materials, manufacturing cost per unit, commercial cost of goods sold, product pricing, or finalized launch economics were provided. As a clinical-stage company, Palvella's value is primarily linked to clinical outcomes, regulatory milestones, intellectual-property protection, manufacturing readiness, financing capacity, and the potential market opportunity for rare diseases rather than current sales.